Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT06145360
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Sponsor
- SINA Health Education and Welfare Trust
- Registry
-
NCT06145360
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT06145360. Randomized; double masking; primary purpose treatment. Start 2023-12-01 (actual); primary completion 2024-03-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
- Condition
- Glucose Metabolism Disorders
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hypoglycemic Agents
- Condition
- Empagliflozin
- Intervention (Drug)
- Empagliflozin 10 MG
- Intervention (Drug)
- Insulin+Metformin+DPP4 inhibitor (DPP4I)
- Lead sponsor
- SINA Health Education and Welfare Trust
- Collaborator
- Horizon Pharmaceutical Pvt Ltd
Record details
- Record id
cardio:ct-nct06145360- Content hash
0b73ee0a6d7bc840693eef31eddb6b74fb111a06e06c1b62f381fe00c41176b5